---
schema_version: "secwatch.filing_event.v1"
accession: "0001425450-24-000002"
form_type: "8-K"
ticker: "KIDS"
cik: "0001425450"
company_name: "ORTHOPEDIATRICS CORP"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:09:25.589078+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OrthoPediatrics prelim Q4 revenue $37.6M (+21%); acquires Boston O&P; 2024 guidance $197-200M

## Summary
- Preliminary Q4 2023 net revenue $37.6M (up 21% YoY); full year $148.7M (up 22%).
- Domestic Q4 rev $28.3M (+24%), int'l $9.3M (+13%). FY domestic $111.0M (+20%), int'l $37.7M (+26%).
- Acquired Boston O&P on Jan 5, 2024 (annual revenue ~$25M); deal expected accretive to adjusted EBITDA in 2024.
- 2024 revenue guidance $197M-$200M (32-34% growth). Cash ~$60M post-acquisition; new $30M term + $50M revolver.
- Acquisition of Boston O&P was also a customer/supplier; Q4 helped ~20k kids, cumulative >710k.

## SEC filing metadata
- accession: 0001425450-24-000002
- form_type: 8-K
- ticker: KIDS
- cik: 0001425450
- company_name: ORTHOPEDIATRICS CORP
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000002/0001425450-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000002/kids-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001425450-24-000002
- JSON: https://secwatch.observer/filing/0001425450-24-000002.json
- Plain text: https://secwatch.observer/filing/0001425450-24-000002.txt

## Key facts
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the fourth quarter ended December 31, 2023 results: revenue $37.6 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $37.6 million
  - Result: preliminary results
  source text: Preliminary unaudited fourth quarter 2023 net revenue is expected to be $37.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000002/0001425450-24-000002-index.htm
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the full year ended December 31, 2023 results: revenue $148.7 million.
  - Period: the full year ended December 31, 2023
  - Revenue: $148.7 million
  - Result: preliminary results
  source text: Preliminary unaudited full year 2023 net revenue is expected to be $148.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000002/0001425450-24-000002-index.htm
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the fiscal year ending December 31, 2024 results: revenue $197 million to $200 million. Guidance initiated.
  - Period: the fiscal year ending December 31, 2024
  - Revenue: $197 million to $200 million
  - Guidance: initiated
  - Result: guidance update
  source text: OrthoPediatrics projects 2024 revenue to be in the range of $197 million to $200 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000002/0001425450-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.